IDO1 and lymphoma: To investigate ICB mechanisms and, at the same time, how the model deals with different tumors and CAR-T cells, we selected data from [11] that presents the action of CAR-T 19 cell immunotherapy against CD19+ lymphoma-expressing IDO in mice.